Hematologic Malignancies Testing Market, By Product (Kits, Services), By Disease (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Myelodysplastic Syndromes), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC)), By End User (Specialty Clinics & Hospitals, Diagnostic Laboratories, Reference Laboratories, Research Institutions), By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, Rest of the World) – Market Size & Forecasting (2016-2028)

The Hematologic Malignancies Testing Market report highlights market opportunities and competitive scenarios for hematologic malignancies testing on a regional and global basis. Market size estimation and forecasts have been provided based on a unique research design customized to the dynamics of the hematologic malignancies testing market. The hematologic malignancies testing market has been segmented by product (kits, services), by disease (leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndromes), by technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (fish), immunohistochemistry (IHC)) and by end user (specialty clinics & hospitals, diagnostic laboratories, reference laboratories, research institutions). Historic back-drop for hematologic malignancies testing market has been analyzed according to organic and inorganic developments to provide precise market size estimations. Also, key factors impacting the growth of the hematologic malignancies testing market have been identified with potential gravity. Major regions covered in the study include North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World.

Market Segmentation:

By Product:

  • Kits
  • Services

By Disease:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Myelodysplastic Syndromes

By Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)

By End User:

  • Specialty Clinics & Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Research Institutions

By Region:

  • North America
    • North America, by Country
      • US
      • Canada
      • Mexico
    • North America, by Product
    • North America, by Disease
    • North America, by Technology
    • North America, by End User
  • Western Europe
    • Western Europe, by Country
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • The Netherlands
      • Rest of Western Europe
    • Western Europe, by Product
    • Western Europe, by Disease
    • Western Europe, by Technology
    • Western Europe, by End User
  • Asia Pacific
    • Asia Pacific, by Country
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Indonesia
      • Rest of Asia Pacific
    • Asia Pacific, by Product
    • Asia Pacific, by Disease
    • Asia Pacific, by Technology
    • Asia Pacific, by End User
  • Eastern Europe
    • Eastern Europe, by Country
      • Russia
      • Turkey
      • Rest of Eastern Europe
    • Eastern Europe, by Product
    • Eastern Europe, by Disease
    • Eastern Europe, by Technology
    • Eastern Europe, by End User
  • Middle East
    • Middle East, by Country
      • UAE
      • Saudi Arabia
      • Qatar
      • Iran
      • Rest of Middle East
    • Middle East, by Product
    • Middle East, by Disease
    • Middle East, by Technology
    • Middle East, by End User
  • Rest of the World
    • Rest of the World, by Country
      • South America
      • Africa
    • Rest of the World, by Product
    • Rest of the World, by Disease
    • Rest of the World, by Technology
    • Rest of the World, by End User

Major Companies:

rcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc.

Years Covered in the Study:

Historic Year: 2016-2017

Base Year: 2018

Estimated Year: 2019

Forecast Year: 2028

Objectives of this report:

  • To estimate the market size for Hematologic malignancies testing market on a regional and global basis.
  • To identify major segments in the Hematologic malignancies testing market and evaluate their market shares and demand.
  • To provide a competitive scenario for the Hematologic malignancies testing market with major developments observed by key companies in the historic years.
  • To evaluate key factors governing the dynamics of Hematologic malignancies testing market with their potential gravity during the forecast period.

Reasons to Buy This Report:

  • Provides niche insights for a decision about every possible segment helping in the strategic decision-making process.
  • Market size estimation of the Hematologic malignancies testing market on a regional and global basis.
  • A unique research design for market size estimation and forecast.
  • Identification of major companies operating in the market with related developments
  • Exhaustive scope to cover all the possible segments helping every stakeholder in the Hematologic malignancies testing market.

Customization:

This study is customized to meet your specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country
  • Product Specific Competitive Analysis

For more information, contact: sales@quincemarketinsights.com